SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
March 1, 2021
(Date of Report/Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
234 Kingsley Park Drive
Fort Mill, South Carolina
(Address and zip code of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act: Common Stock, Par Value $0.01 Per Share; Common stock traded on the New York Stock Exchange; trading symbol UFS.
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Completion of Acquisition or Disposition of Assets.
On March 1, 2021, Domtar Corporation (the “Company”) completed the previously announced sale of the Company’s Personal Care business to affiliates (including Journey Personal Care Corp., the “Purchaser”) of American Industrial Partners, an operationally-oriented middle market private equity firm, for a base purchase price of $920 million in cash, subject to customary adjustments (the “Transaction”). The description of the Transaction does not purport to be complete and is qualified in its entirety by reference to the Securities Purchase Agreement by and among the Company, the Purchaser and the other parties thereto, dated as of January 7, 2021. The Securities Purchase Agreement was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on January 8, 2020, the contents of which are incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective upon the completion of the Transaction, Mr. Michael Fagan, President of the Company’s Personal Care business, will depart from the Company and will continue leading the Personal Care business under its new ownership as CEO.
On March 1, 2021, the Company published a press release related to the matters described in Item 2.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits.
Description of Exhibits
|99.1||Press Release of Domtar Corporation, dated March 1, 2021|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Razvan L. Theodoru
|Name:||Razvan L. Theodoru|
Corporate Law and Secretary
|Date: March 1, 2021|